The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase II trial with safety lead-in to evaluate the addition of sotigalimab, a CD40 agonistic monoclonal antibody, to standard-of-care doxorubicin for the treatment of advanced sarcoma.
 
Sminu (Sam) Bose
No Relationships to Disclose
 
Liner Ge
No Relationships to Disclose
 
Shing M Lee
Consulting or Advisory Role - PTC Therapeutics
Research Funding - AstraZeneca (Inst); Genentech/Roche (Inst); Karyopharm Therapeutics (Inst); Merck (Inst)
 
Brian Andrew Van Tine
Leadership - Polaris
Honoraria - Bionest Partner; Horizon CME; Research to Practice; Targeted Oncology
Consulting or Advisory Role - Adaptimmune; ADRx; Apexigen; Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; Cytokinetics; Daiihi Sankyo; Deciphera; EcoR1 Capital; EcoR1 Capital; EMD Serono; Epizyme; GlaxoSmithKline; Immune Design; Intellisphere; Lilly; Novartis; Pfizer; PTC Therapeutics
Speakers' Bureau - Adaptimmune; GlaxoSmithKline; Lilly; Novartis
Research Funding - GlaxoSmithKline; Merck; Pfizer; TRACON Pharma
Patents, Royalties, Other Intellectual Property - Accuronix Therapeutics- Licensing agreement. Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), • Modular Platform for Targeted Therapeutic Delivery (006755), • Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; Patent on ALEXT3102; Patent on the use of ME1 as a biomarker
Expert Testimony - Health Advances
Travel, Accommodations, Expenses - Adaptimmune; Advenchen Laboratories; GlaxoSmithKline; Lilly
 
Mark Agulnik
Consulting or Advisory Role - AADi; Coherus Biosciences; Regeneron
Speakers' Bureau - Bayer; Deciphera
Research Funding - Exelixis (Inst)
 
Mia C. Weiss
No Relationships to Disclose
 
Kristine Peregrino Lacuna
No Relationships to Disclose
 
Naomi Sender
No Relationships to Disclose
 
Sarah Sta Ana
No Relationships to Disclose
 
Frank J. Hsu
Employment - Apexigen; Oncternal Therapeutics, Inc
Leadership - Apexigen; Oncternal Therapeutics, Inc
Stock and Other Ownership Interests - Abbvie; Amgen; Apexigen; Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - Genzyme (Inst); immune Design (Inst); Stanford University (Inst)
Travel, Accommodations, Expenses - Apexigen; Oncternal Therapeutics, Inc
 
Gary K. Schwartz
Stock and Other Ownership Interests - Bionaut Labs; GenCirq; January Therapeutics
Consulting or Advisory Role - AADi; Agenus; Apexigen; Array BioPharma; Astex Pharmaceuticals; Bionaut Labs; Boehringer Ingelheim; Concarlo; Ellipses Pharma; Epizyme; Gencirq; Ipsen; January Therapeutics; Kirilys Therapeutics; Oncogenuity; OnCusp Therapeutics; PureTech; Sellas Life Sciences; Shanghai Pharma
Research Funding - Adaptimmune (Inst); Astex Pharmaceuticals; Astex Pharmaceuticals (Inst); Calithera Biosciences (Inst); Daiichi Sankyo (Inst); Fortress Biotech (Inst); Incyte (Inst); Karyopharm Therapeutics (Inst); Lilly (Inst); Oxford BioTherapeutics (Inst); SpringWorks Therapeutics (Inst); TopAlliance BioSciences Inc (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - Companion diagnostics for CD4 inhibitors (Inst); patent granted to develop a new technology called PNAs for cancer therapy
Travel, Accommodations, Expenses - Array BioPharma; Boehringer Ingelheim; Epizyme; Epizyme; Epizyme
 
Matthew Ingham
Consulting or Advisory Role - Apexigen; Caris Life Sciences; Daiichi Sankyo; Epizyme; Xencor
Research Funding - Apexigen (Inst); APICES; Mirati Therapeutics (Inst); PTC Therapeutics (Inst)
Travel, Accommodations, Expenses - Genentech